A. Laetrile may be distributed or sold by any person within this state and no special license or prescription shall be required for the sale or distribution of this nutritional supplement.
B. The label or other device affixed to a container containing laetrile shall:
1. Clearly identify the nutritional supplement contained therein as laetrile or amygdalin and, at the option of the manufacturer, vitamin B-17.
2. Include a statement that the nutritional supplement contained therein has not been approved as a treatment or cure for cancer by the food and drug administration of the United States department of health, education and welfare.